Previous Close | 0.0800 |
Open | 0.0400 |
Bid | 0.0000 |
Ask | 0.3800 |
Strike | 30.00 |
Expire Date | 2025-01-17 |
Day's Range | 0.0400 - 0.0800 |
Contract Range | N/A |
Volume | |
Open Interest | 189 |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.